Cancer vaccines have entered a new stage of 'personalized customization.' On August 19, Moderna and Merck jointly announced that the combination regimen of the individualized mRNA therapy intismeran and Keytruda successfully achieved two key objectives—recurrence-free survival and distant metastasis-free survival—in a pre-specified interim analysis. This therapy analyzes tumor mutations in patients and, with the aid of AI technology, selects up to 34 neoantigens to create a tailored mRNA therapy for each patient, training the immune system to precisely identify and eliminate residual cancer cells.